Meitheal Pharmaceuticals Initiates Class II Recall for 16,477 Cetrorelix Acetate Injection Kits Due to Defective Delivery Systems
Meitheal Pharmaceuticals Inc. has initiated a U.S. nationwide Class II recall for 16,477 kits of Cetrorelix Acetate for Injection due to defective delivery systems, specifically missing or duplicated needles. This voluntary action, recall number D-0340-2026, impacts supply chain reliability for a critical human prescription drug. Procurement and regulatory teams must assess immediate supply risks and evaluate Meitheal's quality control processes.
Meitheal Pharmaceuticals Initiates Class II Recall for Cetrorelix Acetate Injection Kits
Meitheal Pharmaceuticals Inc., headquartered in Chicago, IL, has initiated a voluntary, firm-initiated Class II recall for 16,477 kits of Cetrorelix Acetate for Injection, 0.25 mg per vial. This significant regulatory action, identified as recall number D-0340-2026, commenced on February 9, 2026, with the FDA classifying it on February 23, 2026. The recall stems from a critical defect in the product's delivery system: specifically, the injection kits were found to contain missing or duplicated needles. The affected product, bearing NDC 71288-558-90, is from Lot Q4E0112A, with an expiration date of April 30, 2027. The distribution pattern for this recalled product is U.S. Nationwide, indicating a broad impact across the American market. For procurement directors and supply chain VPs, this recall signifies an immediate disruption to the availability of Cetrorelix Acetate, a human prescription drug. The Class II classification means that the use of or exposure to the defective product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. The defect of missing or duplicated needles directly compromises patient safety and the intended therapeutic delivery, necessitating swift action to remove affected units from circulation. Business development executives should note the potential for reputational damage to Meitheal Pharmaceuticals and the broader implications for market confidence in their sterile injectable portfolio.
Implications of a Defective Delivery System for Patient Safety and Market Supply
The core issue identified in this recall—missing or duplicated needles within the Cetrorelix Acetate injection kit—presents direct and severe implications for patient safety and treatment efficacy. A missing needle renders the single-dose kit unusable, potentially delaying critical treatment for patients. Conversely, a duplicated needle could lead to confusion, improper administration, or the use of an incorrect gauge needle, which can cause patient discomfort, injury, or affect drug delivery kinetics. For regulatory affairs heads, this highlights a fundamental breakdown in quality control processes during kit assembly, impacting the integrity of a product intended for precise subcutaneous administration. From a commercial standpoint, the recall of 16,477 kits of Cetrorelix Acetate for Injection due to such a tangible defect can erode trust among healthcare providers and distributors. Procurement teams must immediately assess their inventory of Meitheal's Cetrorelix Acetate (ANDA214540) and identify any affected lots. The financial implications extend beyond the direct costs of the recall to potential lost sales, increased returns, and the considerable expense of investigating the root cause and implementing corrective and preventive actions (CAPA). Business development executives should recognize that such quality issues can deter future partnerships and impact market share, particularly in competitive therapeutic areas where product reliability is paramount.
Market Impact and Supply Chain Considerations for Cetrorelix Acetate
The U.S. Nationwide distribution of the recalled Cetrorelix Acetate for Injection kits means that the impact on supply chains is widespread, affecting pharmacies, hospitals, and clinics across the country. With 16,477 kits subject to recall, procurement directors face the immediate challenge of securing alternative supplies to prevent potential shortages. Cetrorelix Acetate is a critical human prescription drug, and any disruption can have significant consequences for patient treatment plans. The lack of specific alternative suppliers for Cetrorelix Acetate detailed in the current intelligence graph further exacerbates this challenge, compelling procurement teams to rapidly identify and qualify new sources or expand orders with existing, unaffected suppliers if available. Supply chain VPs must initiate comprehensive risk assessments to understand the full extent of exposure, including downstream impacts on patient care and potential contractual obligations. The recall of a product with a specific NDC (71288-558-90) and application number (ANDA214540) requires precise inventory management and communication with all affected stakeholders. This event underscores the necessity of robust supplier qualification programs that include rigorous audits of manufacturing and kitting processes, not just the active pharmaceutical ingredient (API) production. Future procurement strategies should prioritize suppliers with demonstrated excellence in quality control and a strong track record of regulatory compliance to mitigate similar risks.
Broader Regulatory Environment: A Trend of Heightened Quality System Scrutiny
Meitheal Pharmaceuticals' Class II recall for Cetrorelix Acetate is not an isolated incident but rather indicative of a broader trend of heightened regulatory scrutiny by the FDA on pharmaceutical manufacturing and quality control systems. Recent parallel events highlight this persistent focus across the industry. For instance, Essential Wellness Pharma faced a Class II recall in June 2026 for Progesterone Injection due to sterility assurance failures, and Spectra Medical Devices initiated a high-severity Class II recall for Lidocaine HCl Injection, also in June 2026, citing sterility assurance deficiencies. Guardian Drug Co. Inc. similarly faced a nationwide recall for metallic contamination in Calcium Carbonate Antacids in June 2026, while Eugia US LLC initiated a Class III recall for Lidocaine HCl Injection due to labeling deficiencies. These concurrent events underscore the FDA's unyielding expectation for robust Quality Management Systems (QMS) that encompass all aspects of drug product manufacturing, packaging, and kitting. For regulatory affairs heads and business development executives, this pattern signals that the FDA is actively enforcing compliance across various defect categories, from sterility and contamination to packaging integrity and labeling accuracy. Companies must proactively invest in advanced quality control technologies and comprehensive employee training to prevent such issues. Diversifying supplier bases and conducting thorough due diligence on contract manufacturing organizations (CMOs) or kitting partners becomes even more critical to insulate supply chains from systemic regulatory risks impacting the broader pharmaceutical sector.
Navigating the Recall Process: Actions and Future Compliance for Meitheal
As an 'Ongoing' voluntary recall, Meitheal Pharmaceuticals Inc. is currently responsible for several critical actions to address the defective Cetrorelix Acetate injection kits. Regulatory affairs heads understand that Meitheal must conduct a thorough root cause analysis to determine why needles were missing or duplicated in 16,477 kits from Lot Q4E0112A. Following this, the company is expected to implement comprehensive corrective and preventive actions (CAPA) to prevent recurrence. This includes reviewing and potentially overhauling their kitting processes, quality checks, and employee training programs. Effective communication with distributors, healthcare providers, and the FDA is paramount to ensure all affected product is accounted for and removed from the market efficiently. For procurement directors and supply chain VPs, monitoring Meitheal's remediation progress is crucial. The effectiveness and timeliness of Meitheal's response will dictate the duration of supply disruption and the potential for future regulatory actions, such as further recalls or even a Warning Letter if the FDA deems the corrective actions insufficient. Business development executives should evaluate Meitheal's long-term commitment to quality and compliance, as sustained issues could impact their ability to compete and secure new contracts. This recall serves as a critical reminder that a supplier's regulatory posture directly translates into supply chain stability and commercial viability for all partners involved.